000			01503 a2200409 4500
005			20250516015859.0
264		0	_c20110329
008			201103s 0 0 jpn d
022			_a0917-5857
024	7		_aCliCa1101104108 _2doi
040			_aNLM _beng _cNLM
100	1		_aKoike, Tatsuya
245	0	0	_a[ASBMR 2010 report. Meeting report on the ASBMR. Obstacles in medicine for osteoporosis]. _h[electronic resource]
260			_bClinical calcium _cJan 2011
300			_a104-8 p. _bdigital
500			_aPublication Type: Congress
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBone Density Conservation Agents _xadverse effects
650	0	4	_aBone and Bones _xmetabolism
650	0	4	_aCathepsin K _xantagonists & inhibitors
650	0	4	_aDenosumab
650	0	4	_aDiphosphonates _xadverse effects
650	0	4	_aDrug Design
650	0	4	_aEnzyme Inhibitors _xtherapeutic use
650	0	4	_aFemoral Fractures _xetiology
650	0	4	_aHumans
650	0	4	_aOsteoporosis _xdrug therapy
650	0	4	_aProton Pump Inhibitors _xadverse effects
650	0	4	_aRANK Ligand _xtherapeutic use
650	0	4	_aRisk Factors
650	0	4	_aSelective Serotonin Reuptake Inhibitors _xadverse effects
650	0	4	_aSocieties, Medical
650	0	4	_aVitamin D _xanalogs & derivatives
773	0		_tClinical calcium _gvol. 21 _gno. 1 _gp. 104-8
856	4	0	_uhttps://doi.org/CliCa1101104108 _zAvailable from publisher's website
999			_c20474678 _d20474678